Previous close | 15.18 |
Open | 15.37 |
Bid | 15.70 x 200 |
Ask | 15.76 x 400 |
Day's range | 15.25 - 16.17 |
52-week range | 9.90 - 17.73 |
Volume | |
Avg. volume | 540,183 |
Market cap | 1.271B |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WALTHAM, Mass., February 27, 2024--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:
WALTHAM, Mass., February 06, 2024--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
WALTHAM, Mass., February 01, 2024--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024.